2. Search Result
Search Result
Results for "

Synergistic enhancement

" in MedChemExpress (MCE) Product Catalog:

99

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dyes

4

Biochemical Assay Reagents

5

Peptides

7

Inhibitory Antibodies

9

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15244
    Alpelisib
    Maximum Cited Publications
    125 Publications Verification

    BYL-719

    		 PI3K Apoptosis Cancer
    Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
    Alpelisib
  • HY-134816
    D-Glucan

    		Toll-like Receptor (TLR) Metabolic Disease Inflammation/Immunology Cancer
    D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .
    D-Glucan
  • HY-112732B
    Sparfosic acid trisodium
    4 Publications Verification

    		 Apoptosis Metabolic Disease Cancer
    Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .
    Sparfosic acid trisodium
  • HY-112732
    Sparfosic acid
    4 Publications Verification

    		 Apoptosis Metabolic Disease Cancer
    Sparfosic acid, a DNA antimetabolite agent, is a potent inhibitor of aspartate transcarbamoyl transferase, the enzyme catalyzing the second step of de novo pyrimidine biosynthesis. Sparfosic acid synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .
    Sparfosic acid
  • HY-Y0958
    Methoxyamine hydrochloride
    1 Publications Verification

    O-Methylhydroxylamine hydrochloride

    		 DNA/RNA Synthesis Apoptosis Cancer
    Methoxyamine (O-Methylhydroxylamine) hydrochloride is an orally active and potent base excision repair (BER) inhibitor. Methoxyamine hydrochloride binds to 3’ hydroxyl groups that are left behind by 3-methylpurine-DNA glycosylase (MPG) following excision of the damaged base and thus inhibits BER activity. Methoxyamine hydrochloride binds directly to the apyrimidinic (AP) sites. Methoxyamine hydrochloride synergistically enhances the therapeutic efficacy of DNA-damaging agents .
    Methoxyamine hydrochloride
  • HY-12316
    20(S)-Hydroxycholesterol
    3 Publications Verification

    20α-Hydroxycholesterol

    		 Smo Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC50 of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .
    20(S)-Hydroxycholesterol
  • HY-103019
    Enitociclib
    2 Publications Verification

    (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib

    		 Drug Isomer CDK Apoptosis DNA/RNA Synthesis Inflammation/Immunology Cancer
    Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
    Enitociclib
  • HY-119024
    BCI-137

    		SHP1 STAT Cancer
    BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8 + T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields .
    BCI-137
  • HY-107413
    SR11237

    BMS-649

    		 RAR/RXR Tyrosine Hydroxylase Cancer
    SR11237 (BMS-649) GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease .
    SR11237
  • HY-14744A
    Levamlodipine besylate
    2 Publications Verification

    (S)-Amlodipine besylate; Levoamlodipine besylate

    		 Calcium Channel MMP Cardiovascular Disease
    Levamlodipine ((S)-Amlodipine; Levoamlodipin) besylate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate can be used in research related to hypertension and atherosclerosis .
    Levamlodipine besylate
  • HY-128481
    SB24011

    		STING Inflammation/Immunology Cancer
    SB24011 is a STING modulator and a TRIM29-STING protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to STING, thereby upregulating intracellular STING protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1 antibodies, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma .
    SB24011
  • HY-122542B
    PPACK TFA
    2 Publications Verification

    		 Ligands for E3 Ligase Molecular Glues IKZF Family Cardiovascular Disease
    PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (Treg) into effector-like T cells, enhances CD8 + T cell responses, and modulates the Teff:Treg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
    PPACK TFA
  • HY-114243
    DpC

    		NF-κB JNK Caspase Apoptosis Neurological Disease Cancer
    DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
    DpC
  • HY-124447
    BTYNB

    		IGF-1R c-Myc Apoptosis TGF-beta/Smad Cancer
    BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC50 of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma .
    BTYNB
  • HY-N12586
    Pheophytin a

    		ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease Infection Neurological Disease Cancer
    Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC50=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .
    Pheophytin a
  • HY-15244A
    Alpelisib hydrochloride
    Maximum Cited Publications
    125 Publications Verification

    BYL-719 hydrochloride

    		 PI3K Apoptosis Cancer
    Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
    Alpelisib hydrochloride
  • HY-P991149
    Nesfrotamig

    YH32367; ABL105

    		 TNF Receptor Cancer
    Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors .
    Nesfrotamig
  • HY-141831
    STF-1084

    		Phosphodiesterase (PDE) Cancer
    STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity .
    STF-1084
  • HY-P5558
    KLTWQELYQLKYKGI

    		VEGFR Neurological Disease
    KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair .
    KLTWQELYQLKYKGI
  • HY-19518
    Latanoprostene bunod

    NCX116; LBN

    		 Prostaglandin Receptor Neurological Disease
    Latanoprostene bunod (NCX116; LBN) is a nitric oxide-releasing prostaglandin F2α analog. Latanoprostene bunod is a prodrug that, upon instillation into the eye, is hydrolyzed by corneal esterases into two active metabolites: Latanoprost (HY-B0577) and NO. Latanoprost activates the prostaglandin FP receptor to increase the outflow of aqueous humor through the uveoscleral pathway. NO increases aqueous humor drainage through the trabecular meshwork pathway, achieving synergistic enhancement targeting the dual pathways of aqueous humor outflow. Latanoprostene bunod can be used in research related to open-angle glaucoma and ocular hypertension .
    Latanoprostene bunod
  • HY-N0248
    Saikosaponin B2
    2 Publications Verification

    		 HCV P-glycoprotein Infection Cancer
    Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .
    Saikosaponin B2
  • HY-111772A
    (R)-Elexacaftor

    (R)-VX-445

    		 Drug Isomer CFTR Inflammation/Immunology
    (R)-Elexacaftor ((R)-VX-445) is the enantiomer of Elexacaftor (HY-111772). Elexacaftor is an orally active CFTR modulator that targets nucleotide-binding domain 1. Elexacaftor stabilizes misfolded F508del-CFTR protein, enhances its trafficking to the plasma membrane, and significantly improves metabolic stability, thermal stability and ion conductivity. Elexacaftor not only restores chloride transport function in nasal epithelial cells and rescues multiple CFTR mutation subtypes, but also exerts multiplicative synergistic effects with Ivacaftor (HY-13017), and is often used in a triple combination therapy with Tezacaftor (HY-15448). Elexacaftor is widely used in basic and clinical translational research on cystic fibrosis .
    (R)-Elexacaftor
  • HY-P990951
    Vixticibart

    REGN-5381

    		 Natriuretic Peptide Receptor (NPR) Cardiovascular Disease
    Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .
    Vixticibart
  • HY-W134005
    Mg(Ⅱ)-EDTA disodium tetrahydrate

    Ethylenediaminetetraacetic acid magnesium disodium tetrahydrate

    		 Phosphatase Others
    Mg(Ⅱ)-EDTA disodium tetrahydrate is a reversible non-covalent activator of fructose diphosphatase (Km=0.9 μM). Mg(Ⅱ)-EDTA disodium tetrahydrate synergistically activates fructose diphosphatase with free Mg 2+, promotes the hydrolysis of fructose-1,6-bisphosphate at pH≤8, and plays a role in enhancing the activity of key enzymes in gluconeogenesis .
    Mg(Ⅱ)-EDTA disodium tetrahydrate
  • HY-P11111
    QP5

    		Drug Derivative Others
    QP5 is an Amelogenin (HY-P71627)-derived peptide. QP5 binds to hydroxyapatite and demineralized enamel surfaces, temporarily stabilizes amorphous calcium phosphate (ACP), and regulates the crystallization of hydroxyapatite. QP5 promotes remineralization of artificial enamel caries in vitro, and acts synergistically with fluoride to enhance enamel caries remineralization. QP5 can be used in studies related to enamel caries and early enamel caries .
    QP5
  • HY-W016393
    Dihydroconiferyl alcohol

    		Endogenous Metabolite Others
    Dihydroconiferyl alcohol is a cell division factor. Dihydroconiferyl alcohol can be isolated from the American sycamore (Acer pseudoplatanus L.). Dihydroconiferyl alcohol inhibits the degradation of Indole-3-acetic acid (HY-18569). Dihydroconiferyl alcohol can stimulate the growth of soybean and tobacco callus tissue and synergistically enhance Indole-3-acetic acid-induced hypocotyl elongation in cucumber. Dihydroconiferyl alcohol can be used in the research of plant growth regulation .
    Dihydroconiferyl alcohol
  • HY-160696
    ORIC-533

    		CD73 Cancer
    ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka=0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with Daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8 + T cell infiltration and inhibits tumor growth in vivo .
    ORIC-533
  • HY-122542A
    PPACK dihydrochloride
    2 Publications Verification

    Pebac; D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; D-Phe-Pro-Arg-CH2Cl

    		 Ligands for E3 Ligase Molecular Glues IKZF Family Cardiovascular Disease
    PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (Treg) into effector-like T cells, enhances CD8 + T cell responses, and modulates the Teff:Treg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
    PPACK dihydrochloride
  • HY-159647
    PLX-4545

    		Molecular Glues Ligands for E3 Ligase IKZF Family Cancer
    PLX-4545 is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PLX-4545 binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (Treg) into effector-like T cells, enhances CD8 + T cell responses, and modulates the Teff:Treg balance. PLX-4545 also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PLX-4545 can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
    PLX-4545
  • HY-P99916
    Emirodatamab

    AMG-427

    		 FLT3 CD3 TNF Receptor Inflammation/Immunology Cancer
    Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
    Emirodatamab
  • HY-14744
    Levamlodipine
    2 Publications Verification

    (S)-Amlodipine; Levoamlodipine

    		 Calcium Channel MMP Cardiovascular Disease Neurological Disease
    Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
    Levamlodipine
  • HY-P5832
    BMP2-derived peptide

    		TGF-beta/Smad RUNX Metabolic Disease
    BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
    BMP2-derived peptide
  • HY-N0566
    23-Hydroxybetulinic acid

    Anemosapogenin

    		 Apoptosis Autophagy Bcl-2 Family Caspase Survivin p38 MAPK MMP Cancer
    23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer .
    23-Hydroxybetulinic acid
  • HY-176798
    NCI-006

    		Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006
  • HY-161765
    iHSP110-33

    		HSP STAT Cancer
    iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
    iHSP110-33
  • HY-155248
    HL23

    		HDAC Cancer
    HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .
    HL23
  • HY-W570886
    2'-O-MOE-U

    		DNA/RNA Synthesis Cancer
    2'-O-MOE-U is a nucleic acid modification group (Phosphoramidite) with 3'-exonuclease inhibitory activity. 2'-O-MOE-U also exhibits gene silencing activity and double-stranded oligonucleotide stability. By forming steric interactions with 3'-exonuclease residues, 2'-O-MOE-U anchors the 3'-end of the siRNA guide strand in the hAgo2 PAZ domain, thereby regulating double-stranded thermal stability and enhancing base-pairing specificity. 2'-O-MOE-U does not induce IFNα production, can be incorporated at multiple sites of siRNA to enhance RNAi activity, and produces a synergistic effect with 2'-F modification. 2'-O-MOE-U has been widely used in studies related to breast cancer and other diseases .
    2'-O-MOE-U
  • HY-172930
    PVTX-405

    		Molecular Glues IKZF Family Potassium Channel Inflammation/Immunology Cancer
    PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
    PVTX-405
  • HY-155811
    DQP-997-74

    		iGluR Neurological Disease
    DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .
    DQP-997-74
  • HY-157937
    VISTA-IN-3

    		IFNAR Cancer
    VISTA-IN-3 (Compound A4) is a potent VISTA small molecule inhibitor with a KD value of 0.49 μM. VISTA-IN-3 can induce the release of IFN-γ cytokines. VISTA-IN-3 synergistically enhances anti-cancer activity with PD-L1 antibody .
    VISTA-IN-3
  • HY-170779
    DOTA-NI-FAPI-04

    		FAP Cancer
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .
    DOTA-NI-FAPI-04
  • HY-177306
    Opitor-0

    		Dynamin Cancer
    Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase) with an IC50 of 3 μM. Opitor-0 can induce fragmentation of mitochondria and remodeling of cristae, disrupt the stability of OPA1 oligomers, and significantly enhance the release of cytochrome c and induce apoptosis. Opitor-0 has a synergistic antitumor effect with Bcl-2 inhibitors, such as ABT-737 (HY-50907) and Venetoclax (HY-15531). Opitor-0 can be used for the research of malignant tumors that are resistant to Bcl-2 inhibitors, such as triple-negative breast cancer (TNBC) .
    Opitor-0
  • HY-179240
    UNC9815

    		Dopamine Receptor Neurological Disease
    UNC9815 is a D1 dopamine receptor (D1R) orthosteric allosteric modulator (PAM). UNC9815 can dose-dependently enhance the functional efficacy of dopamine in β-inhibitory protein recruitment experiments and cAMP accumulation experiments. When used in combination with other PAMs, UNC9815 exhibits a significant synergistic enhancement effect. UNC9815 can be used to study neurological and psychiatric diseases such as Parkinson's disease and schizophrenia .
    UNC9815
  • HY-179415
    DHFR-IN-24

    		Dihydrofolate reductase (DHFR) Bacterial Infection
    DHFR-IN-24, a benzothiazole derivative, is a dihydrofolate reductase (DHFR) inhibitor. DHFR-IN-24 has intrinsic antibacterial activity against both Gram-positive and Gram-negative strains. DHFR-IN-24 synergistically combines DHFR inhibition with photodynamic therapy (PDT) for enhanced antibacterial activity against multidrug-resistant pathogens .
    DHFR-IN-24
  • HY-161383
    CHK1-IN-9

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 value of 0.55 nM. CHK1-IN-9 can enhance the effect of DNA-damaging drugs on tumor cells. CHK1-IN-9 has synergistic anticancer effects with Gemcitabine (HY-17026) .
    CHK1-IN-9
  • HY-B0317F
    Amlodipine hydrochloride

    		Calcium Channel Infection
    Amlodipine hydrochloride is a biologically active drug used to lower blood pressure and prevent chest pain. Amlodipine hydrochloride has shown synergistic effects with antimicrobial drugs in in vitro studies, especially against carbene peptide-resistant Acinetobacter baumannii. Amlodipine hydrochloride can be used in combination with other antibiotics to enhance the inhibitory effect against resistant bacteria. The use of amlodipine hydrochloride helps reduce the dosage requirements of the drug, reduce toxic effects, and delay the emergence of drug resistance .
    Amlodipine hydrochloride
  • HY-149155
    o-Cymen-5-ol

    		Bacterial Infection
    o-Cymen-5-ol is a broad-spectrum antimicrobial agent with direct antimicrobial activity. o-Cymen-5-ol showed effective minimum inhibitory concentrations (MICs) against a variety of bacteria and fungi, such as Streptococcus mutans and Candida albicans. The combination of o-Cymen-5-ol and zinc showed synergistic effects, enhancing the inhibitory effect against oral pathogens. o-Cymen-5-ol was able to inhibit the glycolysis process and co-enhanced this effect with zinc. o-Cymen-5-ol showed a stronger antibacterial effect in toothpaste than placebo .
    o-Cymen-5-ol
  • HY-178111
    AcrB-IN-6

    		Bacterial Infection
    AcrB-IN-6 is an effective AcrB inhibitor. AcrB-IN-6 The compound inhibits the function of bacterial multidrug efflux pumps, thereby significantly enhancing the antibacterial activity of various antibiotics. AcrB-IN-6 achieves 32-fold MIC reductions in wild-type E. coli BW25113. AcrB-IN-6 exhibits excellent synergistic antibacterial effects, low cytotoxicity and hemolytic properties. AcrB-IN-6 can be used for researching anti-resistant bacteria .
    AcrB-IN-6
  • HY-W016393R
    Dihydroconiferyl alcohol (Standard)

    		Reference Standards Endogenous Metabolite Others
    Dihydroconiferyl alcohol (Standard) is an analytical standard of Dihydroconiferyl alcohol (HY-W016393). This product is intended for research and analytical applications. Dihydroconiferyl alcohol is a cell division factor. Dihydroconiferyl alcohol can be isolated from the American sycamore (Acer pseudoplatanus L.). Dihydroconiferyl alcohol inhibits the degradation of Indole-3-acetic acid (HY-18569). Dihydroconiferyl alcohol can stimulate the growth of soybean and tobacco callus tissue and synergistically enhance Indole-3-acetic acid-induced hypocotyl elongation in cucumber. Dihydroconiferyl alcohol can be used in the research of plant growth regulation .
    Dihydroconiferyl alcohol (Standard)
  • HY-179389
    XDS-23

    		Bacterial Glutathione S-transferase Elastase Infection
    XDS-23 is a selective biofilm inhibitor with an IC50 of 1.26 µM against Pseudomonas aeruginosa. XDS-23 exerts a dual inhibitory effect on the LasI/LasR System (las) and Pseudomonas Quinolone Signal System (pqs). XDS-23 suppress the production of key virulence factors including elastase, pyocyanin, and extracellular polysaccharides. XDS-23 exhibits synergistic antibacterial activity and can enhance the efficacy of multiple antibiotics in both in vitro and in vivo models, while maintaining a favorable safety profile. XDS-23 can be employed for research in combating biofilm-mediated drug-resistant P. aeruginosa infections .
    XDS-23

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: